Annals of the rheumatic diseases
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Read the guideline
Abstract
Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.
More in other
- The Canine Cognitive Dysfunction Syndrome Working Group guidelines for diagnosis and monitoring of canine cognitive dysfunction syndromeEuropean Respiratory Society · 2026
- Chinese guidelines for the clinical application of antibacterial drugs for febrile neutropenia (2026)Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
